Towards a better understanding of cohesin mutations in AML

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Cuartero, Sergi
• dc.contributor.author Innes, Andrew J.
• dc.contributor.author Merkenschlager, Matthias
• dc.date.accessioned 2020-03-25T07:35:47Z
• dc.date.available 2020-03-25T07:35:47Z
• dc.date.issued 2019
• dc.description.abstract Classical driver mutations in acute myeloid leukemia (AML) typically affect regulators of cell proliferation, differentiation, and survival. The selective advantage of increased proliferation, improved survival, and reduced differentiation on leukemia progression is immediately obvious. Recent large-scale sequencing efforts have uncovered numerous novel AML-associated mutations. Interestingly, a substantial fraction of the most frequently mutated genes encode general regulators of transcription and chromatin state. Understanding the selective advantage conferred by these mutations remains a major challenge. A striking example are mutations in genes of the cohesin complex, a major regulator of three-dimensional genome organization. Several landmark studies have shown that cohesin mutations perturb the balance between self-renewal and differentiation of hematopoietic stem and progenitor cells (HSPC). Emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. Among these mechanisms is a role for cohesin in the control of inflammatory responses in HSPCs and myeloid cells. Inflammatory signals limit HSPC self-renewal and drive HSPC differentiation. Consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for AML progression. In this review, we discuss recent progress in understanding cohesin mutations in AML, and speculate whether vulnerabilities associated with these mutations could be exploited therapeutically.
• dc.format.mimetype application/pdf
• dc.identifier.citation Cuartero S, Innes AJ, Merkenschlager M. Towards a better understanding of cohesin mutations in AML. Front Oncol. 2019; 9:867. DOI: 10.3389/fonc.2019.00867
• dc.identifier.doi http://dx.doi.org/10.3389/fonc.2019.00867
• dc.identifier.issn 2234-943X
• dc.identifier.uri http://hdl.handle.net/10230/44013
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Front Oncol. 2019; 9:867
• dc.rights © 2019 Cuartero, Innes and Merkenschlager. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword AML
• dc.subject.keyword Cohesin
• dc.subject.keyword Hematopoiesis
• dc.subject.keyword Inflammation
• dc.subject.keyword Interferon
• dc.subject.keyword Leukemia
• dc.title Towards a better understanding of cohesin mutations in AML
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion